Advertisement

Topics

Companies Related to "Immune cells cast webs that help ovarian cancer" [Most Relevant Company Matches] RSS

10:05 EDT 22nd March 2019 | BioPortfolio

Here are the most relevant search results for "Immune cells cast webs that help ovarian cancer" found in our extensive corporate database of over 50,000 company records.

Showing "Immune cells cast webs that help ovarian cancer" Companies 1–25 of 3,200+

Extremely Relevant

Ovarian Cancer Institute

The Ovarian Cancer Institute is a 501(c)(3) organization dedicated to ovarian cancer research. The work focuses on accurate diagnostics and improved therapeutics. Creators of a first-of-its-kind, early-stage ovarian cancer detection test, the Ovarian Cancer Institute aims to change the future of women suffering from this disease.


Tizona Therapeutics, Inc.

Tizona Therapeutics, Inc., is a privately held immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune disorders. A healthy immune system integrates information from pro-inflammatory and anti-inflammatory cells that regulate the immune system’s function. In cancer, tumor cells evade recognition by c...

Sandy Rollman Ovarian Cancer Foundation

The Sandy Rollman Ovarian Cancer Foundation, a 501 (c) (3) non-profit, now celebrating its 17th year, was created as a tribute to the life, character, and immense strength of Sandy Rollman. Sandy passed away from advanced ovarian cancer in May 2000. Prior to diagnosis, Sandy experienced many textbook symptoms. Her symptoms were whispering only no on...


Avant Diagnostics, Inc.

Avant Diagnostics, Inc. is a medical diagnostic technology company that specializes in large panel biomarker screening. Our first test, OvaDx®, developed in conjunction with Arrayit Corporation (OTCQB: ARYC), detects for pre-symptomatic ovarian cancer. OvaDx® is a sophisticated microarray-based test that measures the activation of the immune system i...

Relevant

NantKwest Inc.

NantKwest (Nasdaq:NK) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body’s first line of defense due to the innate ability of NK cells to rapidly identify ...

IRX Therapeutics, Inc.

IRX Therapeutics is a clinical-stage company developing novel immunotherapies focused on reducing the immune suppression that is seen in the cancer tumor micro-environment, restoring immune function, and activating a coordinated immune response against the tumor. The lead candidate, IRX-2, is a proprietary therapeutic containing numerous active cytokine co...

NantKwest

NantKwest (Nasdaq:NK) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body’s first line of defense due to the innate ability of NK cells to rapidly identify ...

NantKwest, Inc.

NantKwest (Nasdaq:NK) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body’s first line of defense due to the innate ability of NK cells to rapidly identify ...

OncoMab™ GmbH

OncoMab™ GmbH's business is the development of human antibodies for the treatment of cancer. The OncoMab™ way is unique because the antibodies are not developed in mice or by genetic engineering, but are isolated directly from cancer patients. The OncoMab™ antibodies are part of the innate natural immunity against malignant cells. This innate immune system functions as the first defence agai...

Heat Biologics, Inc.

Heat Biologics (www.heatbio.com) (“Heat”) is a clinical-stage company immunotherapy company focused on developing its novel off-the-shelf “ImPACT” (Immune Pan-Antigen Cytotoxic Therapy) therapeutic vaccines to combat a wide range of cancers and other diseases. Heat’s ImPACT Therapy effectively reprograms tumor cells to “pump o...

Surface Oncology, Inc.

Surface is creating the next generation of immunotherapies for cancer. To fully unlock the potential of cancer immunotherapy, Surface is targeting a broader set of immune processes by which cancer cells evade immune recognition and attack. Our programs are built upon emerging, proprietary insights about how to improve the immune system’s recognition a...

Biothera Pharmaceuticals, Inc.

Biothera is a privately held biotechnology company developing Imprime PGG, a clinical stage immunotherapy drug that modulates key immune cells to orchestrate a coordinated immune response to cancer that involves both the innate and adaptive immune system. Proof of concept has been established from single-arm and randomized phase 2 studies in non-small cell...

CytoSen Therapeutics, Inc.

CytoSen is a private biopharmaceutical company on the front line of advancing clinical development of next generation NK cells with the first scalable, therapeutic platform for high dose, cancer-killing NK cells calibrated to each cancer target while reinforcing immune defenses.

Ultimovacs AS

Ultimovacs AS ('Ultimovacs') was established by Inven2 in 2011. The company's goal is to develop technology from the Norwegian Radium Hospital for use in cancer treatment and to make the treatment available to patients. The technology is based on the possibility of controlling the immune system to make it recognise and kill cancer cells. Ultimovacs is carr...

Immune Design Corp.

Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body’s immune system to fight disease. The company’s technologies are engineered to activate the immune system’s natural ability to create and/or expand antigen-specific cytotoxic T cells, while enhancing other immune effectors,...

IMV Inc.

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Corporation’s proprietary drug delivery platform. This patented technology leverages a ...

Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes ...

Siamab Therapeutics, Inc.

Siamab Therapeutics, Inc. is a biopharmaceutical company developing novel cancer immunotherapies targeting cancer-specific carbohydrate antigens seen in multiple solid tumors. Siamab has developed a platform that enables the rapid discovery and development of therapeutic antibodies that bind with unprecedented specificity and affinity to this novel class o...

Biothera

Biothera, a privately held U.S. biotechnology company, is developing Imprime PGG, a late clinical stage biologic that modulates the immune response to cancer. Data from the most recent randomized phase 2 study of Imprime PGG in first line non-squamous non-small cell lung cancer (NSCLC) was featured as a late-breaking abstract in the Immunotherapy of Cancer...

Celldex therapeutics

Celldex is a biotechnology company focused on the discovery, development and commercialization of novel immunotherapeutics including human monoclonal antibodies for the treatment of cancer, infectious diseases, and immune system disorders. We are advancing a pipeline of clinical and pre-clinical product candidates.Our proprietary core technology utilizes human monoclonal antibodies to directly tar...

AmpliMed Corporation

AmpliMed Corporation develops novel drugs for the treatment of cancer. Our lead product, Amplimexon™ (imexon inj.), has particular promise for the treatment of pancreatic cancer, malignant melanoma, lung cancer and multiple myeloma. Other products in our portfolio have promise in ovarian, breast, prostate and other common cancers. Our compounds have novel ways of killing cancer cells which are d...

AC Vaccine technology

The AC Vaccine technology is a therapuetic treatment based on the concept of haptenization. This idea has a long history, beginning with the work of the immunologist and Nobel laureate Karl Landsteiner in the 1920’s. He and other scientists showed in animal models that attaching a small chemical (a hapten) to a protein allowed that protein to be recognized by the immune system even if the anim...

CBT Pharmaceuticals, Inc.

CBT Pharmaceuticals is a biopharmaceutical company focused on developing innovative oncology therapeutics harnessing the immune system and targeting specific molecular pathways to tame cancer. The company is advancing a pipeline of four development-stage assets. CBT-101, is an oral c-MET inhibitor targeting the epithelial to mesenchymal transition (EMT) pa...

Minerva Biotechnologies

Minerva Biotechnologies is a pioneer in the field of stem cells and cancer stem cells. Minerva was first to discover that cancer cells hijack an otherwise normal stem cell growth mechanism, involving a growth factor receptor called MUC1* (pronounced muk 1 star). By studying human stem cells in parallel with human cancer cells, Minerva scientists figured ou...

Tyme, Inc.

Tyme is a pharmaceutical company focused on discovering and developing highly targeted cancer therapeutics for a broad range of oncology indications. Tyme is the originator of what it believes to be a novel, proprietary treatment regimen consisting of a rationally-designed combination of therapeutic agents aimed at exploiting the aberrant metabolic charact...


More From BioPortfolio on "Immune cells cast webs that help ovarian cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks